Cancer Research AACR Conference on Molecular Diagnostics - 2008  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 5057-, May 15, 2007. doi: 10.1158/0008-5472.CAN-06-3365
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McClain, M. R.
Right arrow Articles by Haddow, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McClain, M. R.
Right arrow Articles by Haddow, J. E.
Related Collections
Right arrowRelated Article

Letters to the Editor

How Reliable Are BRCA1/2 Mutation Estimates?

Monica R. McClain, Glenn E. Palomaki and James E. Haddow

Women and Infants Hospital of Rhode Island, Providence, Rhode Island

To the Editor:

Malone et al. (1) recently reported the clinical sensitivity (prevalence) for BRCA1 and BRCA2 mutation testing in a population-based cohort of Caucasian and African-American women with breast cancer. The carrier rates of BRCA1 and BRCA2 mutations in the general population were reported as well. We have developed an approach that integrates these two epidemiologic parameters with two others: cumulative incidence of breast cancer in the general population and penetrance of BRCA1 and BRCA2 mutations (2, 3). We applied this approach to their data to test the plausibility of their parameter estimates.

They report a clinical sensitivity and carrier frequency for BRCA1 mutations of 2.4% and 0.06% (1 in 1,667), respectively. We estimated the cumulative incidence of breast cancer in all women by age 65 (5.8%), taking into account the racial distribution of their cases (DevCan 6.1.1).1 Together, these three parameters can be used to derive the fourth parameter: penetrance of BRCA1 mutations (penetrance was not reported by Malone et al.). Our calculated penetrance of >200% is not plausible and indicates that one or more of the other three parameters are not correct. Using the same approach, the penetrance estimate for BRCA2 mutations is 33%, a plausible, but lower, estimate than found in our report (2).

Their methodology for estimating the mutation carrier frequencies is not described, nor are confidence intervals provided. We question their statement that these carrier frequencies are compatible with earlier estimates. The BRCA1 mutation carrier rate of 1 in 1,667 is considerably lower than the 1 in 800 to 1 in 1,400 contained in the literature (2), whereas the BRCA2 mutation carrier rate is higher (1 in 250 versus 1 in 300 to 1 in 450). These inconsistencies suggest two possibilities for Malone's findings: (a) existing estimates for BRCA1 and BRCA2 mutation carrier frequencies should be revised, or (b) one or more biases are present (e.g., sampling bias or weighting bias). More information is needed from the authors to document the need for the first. Until then, the findings should be interpreted with caution.

Footnotes

1 http://srab.cancer.gov/devcan/ Back

References

  1. Malone KE, Daling, JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res 2006;66:8297–308.[Abstract/Free Full Text]
  2. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28–33.[Medline]
  3. McClain MR, Nathanson KL, Palomaki GE, Haddow JE. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005;7:34–9.[Medline]

Related Article

How Reliable Are BRCA1/2 Mutation Estimates?
Kathleen E. Malone, David R. Doody, Li Hsu, and Elaine A. Ostrander
Cancer Res. 2007 67: 5057-5058. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cancer Res.Home page
K. E. Malone, D. R. Doody, L. Hsu, and E. A. Ostrander
How Reliable Are BRCA1/2 Mutation Estimates?
Cancer Res., May 15, 2007; 67(10): 5057 - 5058.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McClain, M. R.
Right arrow Articles by Haddow, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McClain, M. R.
Right arrow Articles by Haddow, J. E.
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online